Granulocyte Macrophage Colony Stimulating Factor Receptor Subunit Alpha (CDw116 or CD116 or CSF2RA) - Pipeline Review, H2 2016

Published: Nov, 2016 | Pages: 70 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Granulocyte Macrophage Colony Stimulating Factor Receptor Subunit Alpha (CDw116 or CD116 or CSF2RA) - Pipeline Review, H2 2016

Summary

Global Markets Direct's, 'Granulocyte Macrophage Colony Stimulating Factor Receptor Subunit Alpha (CDw116 or CD116 or CSF2RA) - Pipeline Review, H2 2016', provides in depth analysis on Granulocyte Macrophage Colony Stimulating Factor Receptor Subunit Alpha (CDw116 or CD116 or CSF2RA) targeted pipeline therapeutics. 

The report provides comprehensive information on the Granulocyte Macrophage Colony Stimulating Factor Receptor Subunit Alpha (CDw116 or CD116 or CSF2RA), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Granulocyte Macrophage Colony Stimulating Factor Receptor Subunit Alpha (CDw116 or CD116 or CSF2RA) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: 
*Certain sections in the report may be removed or altered based on the availability and relevance of data.
*Updated report will be delivered in 48 hours of order confirmation.

Scope

- The report provides a snapshot of the global therapeutic landscape for Granulocyte Macrophage Colony Stimulating Factor Receptor Subunit Alpha (CDw116 or CD116 or CSF2RA)
- The report reviews Granulocyte Macrophage Colony Stimulating Factor Receptor Subunit Alpha (CDw116 or CD116 or CSF2RA) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in Granulocyte Macrophage Colony Stimulating Factor Receptor Subunit Alpha (CDw116 or CD116 or CSF2RA) targeted therapeutics and enlists all their major and minor projects 
- The report assesses Granulocyte Macrophage Colony Stimulating Factor Receptor Subunit Alpha (CDw116 or CD116 or CSF2RA) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news and deals related to Granulocyte Macrophage Colony Stimulating Factor Receptor Subunit Alpha (CDw116 or CD116 or CSF2RA) targeted therapeutics

Reasons To Buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand the targeted therapy areas and indications for Granulocyte Macrophage Colony Stimulating Factor Receptor Subunit Alpha (CDw116 or CD116 or CSF2RA)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Granulocyte Macrophage Colony Stimulating Factor Receptor Subunit Alpha (CDw116 or CD116 or CSF2RA) development landscape 
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

 Table of Contents

Table of Contents 2
List of Tables 5
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Granulocyte Macrophage Colony Stimulating Factor Receptor Subunit Alpha (CDw116 or CD116 or CSF2RA) Overview 7
Therapeutics Development 8
Granulocyte Macrophage Colony Stimulating Factor Receptor Subunit Alpha (CDw116 or CD116 or CSF2RA) - Products under Development by Stage of Development 8
Granulocyte Macrophage Colony Stimulating Factor Receptor Subunit Alpha (CDw116 or CD116 or CSF2RA) - Products under Development by Therapy Area 9
Granulocyte Macrophage Colony Stimulating Factor Receptor Subunit Alpha (CDw116 or CD116 or CSF2RA) - Products under Development by Indication 10
Granulocyte Macrophage Colony Stimulating Factor Receptor Subunit Alpha (CDw116 or CD116 or CSF2RA) - Pipeline Products Glance 12
Late Stage Products 12
Early Stage Products 13
Unknown Stage Products 14
Granulocyte Macrophage Colony Stimulating Factor Receptor Subunit Alpha (CDw116 or CD116 or CSF2RA) - Products under Development by Companies 15
Granulocyte Macrophage Colony Stimulating Factor Receptor Subunit Alpha (CDw116 or CD116 or CSF2RA) - Products under Development by Universities/Institutes 17
Granulocyte Macrophage Colony Stimulating Factor Receptor Subunit Alpha (CDw116 or CD116 or CSF2RA) - Therapeutics Assessment 19
Assessment by Monotherapy/Combination Products 19
Assessment by Mechanism of Action 20
Assessment by Route of Administration 22
Assessment by Molecule Type 24
Granulocyte Macrophage Colony Stimulating Factor Receptor Subunit Alpha (CDw116 or CD116 or CSF2RA) - Companies Involved in Therapeutics Development 26
Bolder Biotechnology Inc 26
Genzyme Corp 27
Johnson & Johnson 28
OncBioMune Pharmaceuticals Inc 29
Pharmaxis Ltd 30
Savara Inc 31
Targovax ASA 32
XL-protein GmbH 33
Granulocyte Macrophage Colony Stimulating Factor Receptor Subunit Alpha (CDw116 or CD116 or CSF2RA) - Drug Profiles 34
BBT-007 - Drug Profile 34
Product Description 34
Mechanism Of Action 34
R&D Progress 34
GIFT-7 - Drug Profile 35
Product Description 35
Mechanism Of Action 35
R&D Progress 35
molgramostim - Drug Profile 36
Product Description 36
Mechanism Of Action 36
R&D Progress 36
molgramostim - Drug Profile 37
Product Description 37
Mechanism Of Action 37
R&D Progress 37
molgramostim - Drug Profile 41
Product Description 41
Mechanism Of Action 41
R&D Progress 41
ONCOS-102 - Drug Profile 42
Product Description 42
Mechanism Of Action 42
R&D Progress 42
Prostatac - Drug Profile 45
Product Description 45
Mechanism Of Action 45
R&D Progress 45
PXS-2200 - Drug Profile 48
Product Description 48
Mechanism Of Action 48
R&D Progress 48
Recombinant Protein for RSV Infections - Drug Profile 49
Product Description 49
Mechanism Of Action 49
R&D Progress 49
sargramostim - Drug Profile 50
Product Description 50
Mechanism Of Action 50
R&D Progress 50
Vaccine for Prostate Cancer - Drug Profile 52
Product Description 52
Mechanism Of Action 52
R&D Progress 52
XL-150 - Drug Profile 54
Product Description 54
Mechanism Of Action 54
R&D Progress 54
Granulocyte Macrophage Colony Stimulating Factor Receptor Subunit Alpha (CDw116 or CD116 or CSF2RA) - Dormant Projects 55
Granulocyte Macrophage Colony Stimulating Factor Receptor Subunit Alpha (CDw116 or CD116 or CSF2RA) - Discontinued Products 57
Granulocyte Macrophage Colony Stimulating Factor Receptor Subunit Alpha (CDw116 or CD116 or CSF2RA) - Featured News & Press Releases 58
Nov 10, 2016: Targovax granted European Patent for ONCOS platform lead product, ONCOS-102 58
Oct 24, 2016: Immunotherapy Expert Dr. Brian Barnett Joins OncBioMune Scientific Advisory Board 58
Oct 21, 2016: Targovax presents ONCOS-102 scientific rationale at the European Society of Gene and Cell Therapy 59
Oct 19, 2016: OncBioMune Receives Notice of Patent Allowance for Novel Cancer Vaccine ProscaVax in Mexico 60
Oct 17, 2016: Targovax to Present at the ESGCT/ISSCR Stem Cells & Gene Therapy Symposium 60
Oct 06, 2016: BARDA Awards $37.6 million Contract to Sanofi to Supply Leukine (sargramostim) for Potential Public Health Emergency 61
Sep 26, 2016: OncBioMune CEO Dr. Jonathan Head to Present Abstract on Prostate Cancer Vaccine at Second CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference: Translating Science Into Survival 61
Aug 08, 2016: Latest Data From Phase 1 Trial of ProscaVax for Prostate Cancer Reinforces Safety and Benefit of Novel Cancer Vaccine 62
Jul 20, 2016: Pre-Clinical Research Supports Additional Studies of OncBioMune Technology for Breast Cancer Vaccine 63
Jul 13, 2016: OncBioMune Submits Protocol to Initiate Phase 2/3 Trial of ProscaVax for Prostate Cancer 63
Jul 05, 2016: Targovax presents encouraging preclinical data on ONCOS-102 64
Jul 01, 2016: Targovax recruits the first patient in a trial with the oncolytic virus ONCOS-102 in malignant pleural mesothelioma 65
Jun 14, 2016: Targovax granted US Patent for oncolytic virus ONCOS-102 65
Jun 14, 2016: OncBioMune Provides Corporate Update; ASCO Reinforces Market Opportunity for New Prostate Cancer Vaccine as Phase 2 Trial Approaches 66
Jun 09, 2016: Targovax receives regulatory approval in Spain to conduct a clinical trial with its oncolytic virus ONCOS-102 67
Appendix 69
Methodology 69
Coverage 69
Secondary Research 69
Primary Research 69
Expert Panel Validation 69
Contact Us 69
Disclaimer 70

List of Tables

Number of Products under Development for, H2 2016 8
Number of Products under Development by Therapy Area, H2 2016 9
Number of Products under Development by Indication, H2 2016 11
Comparative Analysis by Late Stage Development, H2 2016 12
Comparative Analysis by Early Stage Products, H2 2016 13
Comparative Analysis by Unknown Stage Development, H2 2016 14
Number of Products under Development by Companies, H2 2016 15
Products under Development by Companies, H2 2016 16
Number of Products under Investigation by Universities/Institutes, H2 2016 17
Products under Investigation by Universities/Institutes, H2 2016 18
Assessment by Monotherapy/Combination Products, H2 2016 19
Number of Products by Stage and Mechanism of Action, H2 2016 21
Number of Products by Stage and Route of Administration, H2 2016 23
Number of Products by Stage and Molecule Type, H2 2016 25
Pipeline by Bolder Biotechnology Inc, H2 2016 26
Pipeline by Genzyme Corp, H2 2016 27
Pipeline by Johnson & Johnson, H2 2016 28
Pipeline by OncBioMune Pharmaceuticals Inc, H2 2016 29
Pipeline by Pharmaxis Ltd, H2 2016 30
Pipeline by Savara Inc, H2 2016 31
Pipeline by Targovax ASA, H2 2016 32
Pipeline by XL-protein GmbH, H2 2016 33
Dormant Projects, H2 2016 55
Dormant Projects (Contd..1), H2 2016 56
Discontinued Products, H2 2016 57